Pegex 6mg Injection

Pegex 6mg Injection contains the active ingredient pegfilgrastim, a granulocyte colony stimulating factor approved by the FDA. It is indicated to decrease the risk of febrile neutropenia (fever or infection occurring with low white blood cell count) and reduce the duration of neutropenia (low white blood cell count) in patients receiving bone marrow suppressive chemotherapy. The injection is also indicated to increase survival in patients exposed to radiation therapy that causes severe and life-threatening bone marrow damage.

Pegfilgrastim acts on blood-forming cells, stimulating cell multiplication and activating cell function. It is a protein synthesized through biotechnology using E. coli bacteria. As a member of the cytokine protein family, pegfilgrastim closely resembles the natural granulocyte-colony stimulating factor produced by the body. White blood cells are essential for fighting infection. These cells are highly sensitive to chemotherapy effects, which can reduce their number. When white blood cell count decreases, the body may lack sufficient cells to combat bacteria, increasing infection risk.

Before starting treatment with this injection, inform your physician if you have or have ever had liver disease, fever or infection, kidney problems, heart problems, or a family history of kidney diseases. Do not use this injection if you are allergic to pegfilgrastim, filgrastim, or any other ingredients in the formulation. Report symptoms of left upper abdominal pain, shoulder pain, and respiratory problems immediately to your doctor. The most common side effects are pain in the bones, arms, and legs.

Pegex 6mg is a prescription Injection, and it is used to treat Decrease the chance of infection caused by low levels of white blood cells in patients with certain types of cancer (non-myeloid) receiving bonemarrow suppressing anti-cancer drugs. To increase the survival rate in patients receiving radiation therapy that suppresses bone marrow activity.

Pegex 6mg Injection is a colony-stimulating factor that exerts its action by acting on blood-forming cells by binding to specific cell surface receptors, thereby inducing cell division, multiplication, and cell functional activation.

The Injection will be administered in the fatty tissues just under your skin (subcutaneously) by a qualified healthcare professional in a hospital setting. The dose and frequency of administration will be decided by your doctor based on your disease condition and other factors. If your physician decides that Pegex 6mg Injection can be administered at home by you or your caregiver, then read the “Instructions for use” carefully from the package insert that comes with the Injection. Your doctor or other healthcare professionals will train you on self-administration. Do not administer the Injection if you have not been trained and not sure about the administration procedure.

Side effects are unwanted symptoms caused by Injections. Even though all drugs cause side effects, not everyone gets them. Common Pain in the bones, joints and muscles Pain at the site of Injection Itchiness and skin rash Nausea Headaches Dizziness and tiredness Serious Inflammation of Aorta Capillary leak syndrome (plasma leaks out of tiny blood vessels) Hypersensitivity reactions Changes in urine color Swelling in hands, feet, face, and abdomen Difficulty in breathing Sickle cell anemia

Inform your physician if you are experiencing any symptoms of swelling in the face, feet, hands, and abdomen, difficulty in breathing, sudden drop in blood pressure, left abdominal pain, weakness, and skin rashes. Pegex 6mg Injection is a dose-based injection, and it should not be administered in patients weighing less than 45kg from a pre-filled syringe. Read the package insert carefully if you are self-administering the Injection. This Injection may cause lung, liver or kidney problems. Your physician may advise you to take laboratory tests regularly to monitor the effectiveness of the therapy.